Status:
COMPLETED
Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Metastatic Anal Canal Cancer
Human Papillomavirus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Complete response is a rare event in metastatic anal cancer in the case of unresectable recurrence after radiochemotherapy. In the University Hospital Center of Besançon, 8 patients with metastatic a...
Eligibility Criteria
Inclusion
- ECOG performance status ≤ 1
- patient with metastatic anal cancer HPV+
- presence of a measurable target lesion according to radiological criteria (Recist V1.1)
- patient with more than 12 months of complete remission of metastatic anal cancer according to radiological criteria (Recist V1.1)after treatment by DCF regimen (Docetaxel, Cisplatin and 5-Fluorouracil)
Exclusion
- pregnancy or lactation
- patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01845779
Start Date
September 1 2012
End Date
December 31 2019
Last Update
May 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Oncology - University Hospital of Besançon
Besançon, France, 25000